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MULTICOMPARTMENT HARD CAPSULE

para?inic wax. The suppository shell can be composed of

WITH CONTROL RELEASE PROPERTIES

the same ingredients and melts at 37° to 38° C.

U.S. Pat. No. 3,415,249 to Sperti discloses a suppository
comprising a ?rst and second body. The ?rst body consists

This application is a continuation of application Ser. No.
08/094,637 ?led Jul. 21, 1993 now abandoned.

of a suppository base and a coating. The base may be a

polyethylene glycol and the coating may also be a polyeth
ylene glycol. Sperti also discloses that the base of the
coating should have a substantially lower melting point than
the base of the suppository. Sperti discloses that it is possible

TECHNICAL FIELD
The present invention relates to a hard capsule which can
deliver a desirable agent, such as a drug or an odoriferous

agent, over a prolonged period of time.
The invention provides a hard capsule made from gelatin,
starch or a hydrophilic polymer, such as hydroxypropyl

methylcellulose (HPMC) or carboxymethyl cellulose, which
by virtue of its design and composition provides an imme
diate and sustained mode of release of its pharmacologically

10

to locate a thin barrier layer over the body of the suppository
prior to the application of the coating. Such an additional
layer may be of moisturized gelatin. The coating can contain
an anesthetic substance and the body of the suppository

15

of cellular respiration. ‘The thin barrier layer does not contain

contains a medicament such as an agent for the stimulation

active or otherwise desirable components in an aqueous

a medicament.

environment.

U.S. Pat. No. 4,707,362 to Nuwayser discloses a vehicle
for providing both rapid release and prolonged release of a
drug. The vehicle may be a vaginal suppository. The sup
pository body melts at body temperature and includes a

BACKGROUND AKI‘

Suppositories are known to be useful in the delivery of
drugs. For example, U.S. Pat. No. 3,814,809 to Gordon et al.
discloses a vaginal suppository composed of CARBO

bioerodible ?lm insert. The suppository may contain a

spermicide such as Nonoxynol-9. The suppository does not
include three compartments for differential drug release.

WAXTM and a medicament such as prostaglandin.

Suppositories may be multilayered. Japanese Publication

25

Nos. JP-150,421 and JP-l50,422 disclose a multi-layered
suppository. In each layer, one or more medical components
are mixed with one or more water-soluble base materials

such as Macrogol. The suppository disclosed in the Abstract

water-soluble slow release material in which are dispersed

of 150,422 contains two layers and does not contain an outer

particles comprising an active ingredient. The formulation

coating layer.

also contains a secondary matrix of water-soluble dispers
ible slow release material in which the granules of medica
ment are dispersed. At least one of the matrices may be

Japanese Application 065289 discloses a two-layered

suppository comprising successively charged molten water
soluble bases (Macrogol or glycerogelatin). The suppository
includes a water-soluble base layer in the lower half of the
suppository and a fat-soluble base layer in the upper half.

35

The coated suppository is a slow-releasing rectal supposi
tory and does not include an outer coating layer which
includes a drug to provide immediate drug release.
UK Patent 1,431,092 discloses that certain types of sup
positories have thin protective coatings, which may also

gelatin. The suppository can contain secondary granules
which are of a larger size than primary granules, and if
desired tablets or capsules may be enteric ?lm or sugar
coated. Rhodes does not disclose a fast releasing outer

The suppositories are both rapid and long-acting. This
suppository does not include an outer coating layer which
includes a drug to provide immediate drug release.
Japanese Application 102,055 discloses a slow-release
rectal suppository which is the product of connecting a
suppository prepared with a water-soluble base material and
a suppository prepared with a water-soluble base material
and surface coated with a base material which is insoluble in
water and which does not melt quickly at rectal tempera
tures. The water-soluble base material may be a mixture of
gelatin and glycerine or a mixture of two or more Macrogol.

U.S. Pat. No. 4,880,830 to Rhodes discloses a slow

release formulation for the preparation of tablets, capsules,
suppositories or implants (see column 2, line 59) which
comprises granules which are composed of particles com
prising an inactive ingredient and a primary matrix of

coating containing a medicament.
U.S. Pat. No. 4,828,840 to Sakamoto et al. discloses a
sustained released formulation of a water-soluble active

ingredient comprising an inert core, a powder coating layer
surrounding the core, a second powder coating layer sur
rounding the ?rst powder coating layer, and a ?lm coating
45

layer surrounding the second powder coating layer. The ?lm

coating layers include polyvinylpyrrolidone, hydroxypropyl
methylcellulose and starches. The ?lm coating layer does
not contain a medicament.
50

An example of a controlled release product which is
commercially available is the product PROCARDIA XLTM
distributed by P?zer (1235 East 42nd St., New York, N.Y.).
This is an extended release tablet which is designed to

provide the cardiovascular drug nifedipine at an approxi

contain medicarnents or the like are, and which are some

contain a medicament for immediate drug release.
U.S. Pat. No. 3,122,475 to Schaeppi discloses a multi

mate constant rate over 24 hours (PDR 47th Ed 1993,
Medical Economics Data). In PROCARDIA XLTM the tablet
depends for its action on the existence of an osmotic gradient
between the contents of its bilayer core and the ?uid in the
GI tract. Drug delivery is essentially constant as long as the
osmotic gradient remains constant, and then it gradually
falls to zero. Upon swallowing, the biologically inert com
ponents of the tablet remain intact during GI transit and are

layer suppository containing sequentially acting medica

eliminated in the feces as an insoluble shell. The osmotic

ments e?iective for treating heart decompensation. In this
suppository, the core represents about one-?fth to one-third
of the total weight of the suppository and the shell represents
?re remaining four-?fth to two-thirds. The suppository core

gradient in this tablet is achieved by the introduction of a

times used to reduce premature melting. This outer coating
appears to teach away from the use of a fast releasing outer

coating which contains a drug.
U.S. Pat. No. 3,197,369 to Widman et al. discloses coated

gelatin capsules. The coating of the gelatin capsule does not

can be composed of cocoa butter, solidi?ed glycerin or

55

semipermeable membrane surrounding an osmotically
65 active drug core. The core is divided into two layers: an

“active” layer containing the drug, and a “push” layer

containing pharmacologically inter (but osmotically active)

5,672,359
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components. As water from the gastrointestinal tract enters
the tablet, pressure increases in the osmotic layer and

partment of the capsule from 45 to 50 minutes after immer
‘sion of the capsule into an aqueous medium; release of the
drug or active agent from the intermediate compartment

“pushes” against the drug layer, releasing the drug through
a precision laser drilled tablet ori?ce in the active layer.
There is a need in the medical and pharmaceutical disci

occurs from 10 min. to 1.5 hours after immersion of the

capsule in a liquid medium and the release of the drug from
the intermediate compartment is completed from 4 to 5

plines for a drug delivery system which incorporates phar
rnacologically active components in three or more di?eren

hours after immersion of the capsule in a liquid medium. The
initial release of the drug or active agent from an inner

tially releasing drug compartments. This need particularly
exists in vaginal applications wherein the release of the drug
has to begin shortly after administration such as in the case
of a spermicide or an anti-HIV agent and in which the drug
release must conn'nue for several hours to achieve the

compartment of the drug delivery system occurs from about
10

desired sperrnicidal and anti-HIV result.

The drug delivery system of the present invention pro
vides a capsule of differentially releasing distinct compart

15

ments. The outer compartment provides a rapid release of a

portion of the delivery system. And the innermost compart

desired sperrnicidal and. anti-HIV result.
The capsule of invention provides an ideal vehicle for

ment provides a slow release component of the delivery

system. The drug delivery system overcomes inadequacies
of prior capsule formulations to provide controlled imme

colonic drug delivery of peptide drugs and an inexpensive
method for drug delivery to the gastrointestinal tract.
The multicompartment coated capsule of the invention, in

diate and prolonged release of a desired agent in an aqueous
environment.

an additional embodiment comprises a “One a Day” single
25

The present invention provides a hard capsule drug deliv

dosage control release capsule.
Other objects, features, aspects and advantages of the
invention will be more apparent to those of skill in the

ery system comprising at least one inner compartment, at
least one intermediate compartment surrounding the at least

dispensing art from the following detailed speci?cation
taken in conjunction with the drawing ?gures and the
accompanying claims.

one inner compartment and at least one outer compartment

surroundingthe at least one intermediate compartment, and
wherein each compartment comprises at least one drug

component.
The present invention provides a drug delivery system of
a hard capsule comprising an outer compartment, an inter
mediate compartment and an inner compartment, wherein
the rate of release of the drug component of the outer
compartment is faster than the rate of release of the inter
mediate compartment, and the rate of release of the inter
mediate compartrnent is faster than the rate of release of the

The invention also provides a drug delivery system useful
in vaginal applications wherein the release of the drug
begins shortly after administration such as in the case of a
spermicide or an anti-HIV agent and in which the drug
release must continue for several hours to achieve the

drug incorporated into the outer compartment. An interme
diate compartment provides an intermediary speed release

DISCLOSURE OF THE INVENTION

1 to 2 hours after irmnersion of the capsule in a liquid
medium and the release of the drug from an inner compart
ment is completed from about 7 to 8 hours after immersion
of the capsule in a liquid medium.

35

inner compartment.

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a perspective view of the capsule of the
present invention.
FIG. 2 shows a chart indicating the rate of release of an
active component measured by the rate of iodine release
from the outer compartment of the capsule.
FIG. 3 shows a chart indicating the rate of release from the
middle compartment of a hard capsule packed with 170 mg
of PVP-I/N-9 and 170 mg of Ac-Di-Sol.
FIG. 4 shows a chart indicating the rate of release ?'om the

In a further embodiment, the invention provides a hard

inner compartment of a hard capsule packed with ?ve
PCP-I/N-9 pellets dispersed into a powder containing 170

capsule drug delivery system comprising at least one inner

compartment, at least one intermediate compartment sur
mg of PVP and 170 mg of AC-DI-SOL. The term AC-TI
rounding the at least one inner compartment and at least one 45 SOL used throughout the speci?cation means crosscarmel
outer compartment surrounding the at least one intermediate
lose sodium. “W/W" means “weight %” as used throughout

compartment, and wherein each compartment comprises at
least one drug component, wherein the outer compartment
begins release of the drug component about 1 minute after
immersion of the hard capsule into an aqueous medium and

completes release of the drug component about 45 to 50

the speci?cation.
50

ments.
55

ing the steps of forming a capsule comprising at least one
inner compartment;

surrounding the at least one intermediate compartment, and
each compartment comprises at least one drug component or

active agent.

intermediate compartment; and
surrounding the intermediate compartment with at least
one outer compartment, wherein each compartment
comprises at least one drug component and wherein the
outer component comprises a mixture of the drug
component and an excipient coating the intermediate
compartment.

'

The capsule includes at least one inner compartment, at
least one intermediate compartment surrounding the at least
one inner compartment and at least one outer compartment

surrounding the inner compartment with at least one

An additional embodiment of the invention provides
complete drug or active agent release from the outer com

into a delivery system which incorporates pharmacologi
cally active components in three or more distinct compart

minutes after immersion of the capsule into an aqueous
medium
A still further embodiment of the invention provides a

method for manufacturing a drug delivery system compris

DESCRIPTION OF THE INVENTION
The present invention relates to a hard capsule formulated

Preferably in the hard capsule the rate of release of the
drug component of the outer compartment is faster than the
rate of release of the intermediate compartment, and the rate
of release of the intermediate compartment is faster than the
rate of release of the inner compartment.
65

The capsule may be made from gelatin, starch, hydrox
ypropyl methylcellulose or carboxymethyl cellulose, for

example.

5,672,359
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.

When three compartments are utilized in the capsule, the
outer compartment may incorporate a drug, active agent or
odoriferous agent and excipients into a layer which coats
and thus surrounds the intermediate component of the cap

agent has to begin shortly after administration such as in the
case of a spermicide or an anti-I-HV agent and in which the

drug release must continue for several hours to achieve the
desired spermicidal and anti-HIV result

sule. This outer component represents the rapid release
portion of the delivery system. The intermediate compart

Applications of the drug delivery system include, but are
not limited to the delivery of drugs for the treatment of

ment comprises a powder formulation which represents the
intermediate rate of release portion of the delivery system.

The innermost compartment incorporates the active ingre
dient or ingredients in a multiparticulate form, such as small
pellets which may be coated or uncoated, and represents the

10

internal use for controlled release delivery of drugs or
vitamin nutritional supplements, or any other bene?cial

slow release compartment of the delivery system.
Thus the drug delivery system of the invention possesses
the ability to deliver a desired drug or combination of drugs
from a period of time ranging from seconds after adminis
tration to several hours.
The rate of release of the drugs from a capsule consisting

agent. The capsule is preferably used in the delivery of
peptide drugs to the colon.
15

The outer compartment or coating preferably contains a

drug component or active agent and an excipient compo
nent. In one embodiment of the drug delivery system the
drug component or active agent and the excipient compo

of three or more compartments may be controlled. An
alteration in its composition as well as in the temperature

will result in the changed release pro?le. The optimal ratio
of drug to excipient in the outer compartment may be
adjusted based on the drug properties and the required
coating extent of the outer surface of the capsule according

vaginal yeast infections and for rectal use for the delivery of
hemorrhoidal drugs. The capsules may contain odoriferous
agents for vaginal or other delivery. The drug delivery
system according to the present invention may also ?nd

20

nent are solubilized in alcohol, such as methanol or ethanol.

Preferably the concentration of the drug component or active
agent is 8% to 50% w/v. The excipient component may
include CARBOWAXTM 8,000, CARBOWAXTM 4,600,

CARBOWAXTM3350 or CARBOWAXTM 1,450, hydrox

to methods known in the art. The release of the drug or drugs
ypropyl methylcellulose (HPMC) or mixtures thereof. CAR
from the outer compartment of the capsule can begin as 25 BOWAXTM is a trademark of Union Carbide for polyethyl
quickly as about one minute after the capsule’s immersion
ene glycol polymers.
into an aqueous medium, and a complete release of the drug
Additionally, when the above solid components are solu
in the outer compartment can occur within a period of 45 to
bilized in water, methanol or ethanol, they form a dipping
50 minutes after immersion.
solution or spray coating, the composition of which ranges
30
The intermediate compartment may contain up to 300 mg
from about 10%:0%:8% to about 12.5%:10%:50% of
of a drug powder in an O-size capsule. Although a O-size
Carbowaxesm, hydroxypropyl methylcellulose and drug,

capsule is preferred, any size capsule may be used. Capsule
size is directly related to the method of administration of the
capsule. Larger capsules may be hard to swallow. If the

capsule is for gastrointestinal administration O-size, OO-size
or OOO-size capsules are preferred. Larger capsules may be

35

used for vaginal or rectal administration.
Release of the drug ?om the intermediate or middle
compartment may begin at approximately one hour after
immersion of the capsule in an aqueous medium, and release
may be completed within 4 to 5 hours after administration an

respectively. A preferred method for constructing the outer,
rapid release compartment of the delivery system consists of
an appropriate mixing of the desired drug with polyethylene
glycol CARBOWAXTM 8,000; 4,600; 3,350; and 1,450 or a
mixture of CARBOWAXTM, HPMC and the drug. The hard
capsule can be dipped several times or spray coated until the

appropriate outer compartment is formed. This procedure
may be utilized to coat hard capsules made from gelatin,
starch or a hydrophilic polymer such as HPMC.
If the drug component or active agent does not include a

immersion in an aqueous medium. The intermediate com

derivative of polyvinylpyrrolidone (PVP) as an active ingre
dient (such as PVP-I), the excipient used in the capsule may

partrnent comprises a powder drug component or active
agent. The release time of the drug from this compartment
could be changed by an appropriate alteration in its formu

comprise polyvinylpyrrolidone. Preferably the concentra
tion of the excipient component is 10% to 12.5% w/v, and
alternatively the concentration of the excipient is 0% to 10%

lation.
The drug component or active agent contained in an inner

WW. When the above solid components are solubilized in
water, methanol or ethanol, they form a coating solution.

compartment of the capsule is preferably a pellet formula

tion. The inner compartment consists of one or more pellets 50 The composition of the coating solution preferably ranges
from 10%-12.5% CARBOWAXTM, from 0%—l0% HPMC,
which may be coated or uncoated. The coating solution for

and from 8%—50% drug.

the pellet is adapted for sustained release in the gastrointes
?nal tract and may contain mixtures of waxes with glycerol

According to the present invention, the drug delivery

monostearate, stearic acid, palmitic acid, shellac and zein
polymers, ethylcellulose acrylic resins and other materials as

system includes an intermediate compartment comprised of
55

a drug component or active agent and a disintegrant com

outlined in Remington ’s Phamtaceutical Sciences. The rate
of release of the drug from the inner compartment is a
function of the rate of disintegration of the hard capsule wall
and that of the pellets. The size of the pellet may be adjusted
in accordance with the amount of drug to be delivered and

ponent. The disintegrant component may comprise from 100

the desired rate of drug release. For example, the pellets may

of the capsule wall, upon which the contents of the capsule
are delivered. The proportion of the disintegrant to the drug
determines the time of release of the capsule contents in to
tie surrounding medium.
In a preferred embodiment the concentration of the drug
component or active agent in the intermediate compartment
ranges from about 125 to about 170 mg.

range in size from about 1 mm to about 3 mm in diameter.

The release of the drug from an inner compartment is
completed from about 7 to 8 hours after immersion of the
capsule in a liquid medium.
65

The drug delivery system is particularly useful in vaginal
applications wherein the release of the drug or odoriferous

mg to 180 mg of Ac-Si-SolTM, which is a modi?ed cellulose
gum which is an internally crosslinked form of a sodium salt

of carboxymethyl cellulose of USP pm-ity. The disintegrant
absorbs water and swells and thus contributes to the collapse

5,672,359
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The inner compartment may also be comprised of a drug
component or active agent and an excipient component.
Preferably the excipient of the inner compartment is selected
from lactose, magnesium stearate, Ac-Di-Sol, or calcium
phosphate, or mixtures thereof. The inner compartment of

fate. Nonoxynol-9 is preferred. Vaginal drugs such as

miconazole, acyclovir, clotrimazole, ticonizole, hormones
such as estrogens; metronidazole, sulfas including

sulfabenzamide, sulfacetarnide, sulfacytine, sulfatrizaole;

tetracycline hydrochloride, erythromycin, achromycin,
chloromycetin, penicillin, chlortetracycline bacitracin, and

the drug delivery system according to the invention
includes, in a preferred embodiment, a pellet formulation
comprises from 7% to 70% w/w drug component or active
agent, from 10% to 84% w/w lactose, and from 6% to 20%
w/w magnesium stearate. The pellets are compressed using
pressure of 600-1000 pounds.
The inner compartment of the drug delivery system of the
present invention is comprised of the desired drug formu
lated in a multiparticulate form. For example, pellets weigh
ing 30 mg each (approximately 3 mm in diameter) can be
dispersed into the inner compartment of the hard capsule.
The pellets contain the drug and several excipients which
determine their physical characteristics and their rate of
dissolution in an aqueous medium

nystatin may be administered in the drug delivery system
according to the present invention. Anti-in?ammatory
agents such as aspirin, chlocortolone pivalate,
hydrocortisone, tolmetin sodium, and indomethacin may
also be administered. The drug delivery system is also useful
in the delivery of germicides, such as benzalkonium and
chlorhexidine and virucides, such as anti-HIV drugs.

The solubility of the drug in the coating solvent does
15

ment is completed from about 7 to 8 hours after immersion

active agent by coating the capsule with a coating suspen
sion as set forth in example 6.

In a preferred embodiment, the capsule of the invention is
used for the colonic delivery of peptide drugs. Certain
peptide drugs can be delivered from the colon if they are

protected from proteolytic destruction in the particular site
of the gastrointestinal tract (GI).
25

Absorption enhancers may be used to facilitate the

absorption of these relatively large peptide molecules. Con
sequently to achieve drug absorption of these peptides, the
drug formulation preferably contains a protease (proteolytic
enzyme) inhibitor and one or more absorption enhancers.

See M. E. K Kraeling and W. A. Ritschel, “Development of
Colonic Release Capsule Dosage Form and the Absorption
of Insulin”, Meth. Find. Exp. Clin. Pharmacol. (1992), Vol.

14(3), pp. 199-209, incorporated herein by reference.
In one embodiment the multicompartrnent capsule of the
35

present invention permits the release of the absorption
enhancer(s) and the protease inhibitor prior to the release of
the peptide drug. This offers the advantage that the mem
brane of the colon is predisposed to permit the crossing of
the peptide drug and thus -the colon would be free of
proteolytic activity at the time the drug is released from the

of the capsule in a liquid medium.
A preferred method for manufacturing a drug delivery
system according to the invention includes the steps of
forming a capsule comprising at least one inner compart
ment; surrounding the inner compartment with at least one
intermediate compartment; and surrounding the intermedi

capsule.
In this embodiment, the protease inhibitor and the absorp
tion enhancers could either be present in the outer compart

ate comparunent with at least one outer compartment, with

each compartment comprising at least one drug component
or active agent and wherein the outer component comprises

ment or the outer and intermediate compartments of the

multicompartment capsule. The peptide drug may be intro

a mixture of the drug component or active agent and an

duced in the intermediate compartment and the inner slow

excipient coating the intermediate compartment.
Coating of the capsule wall which surrounds the interme

diate compartment may be accomplished by dipping the
capsule in the mixture of drug and excipient. Coating may
also be accomplished by spray coating the capsule with the
mixture of drug and excipient. Conventional dipping and

coating procedure can be practiced with a highly soluble
drug as well as a completely insoluble drug component or

'

Also contemplated within the scope of the present inven
tion is a drug delivery system comprising a hard capsule
with differential rates of release of the drug component or
active agent as outlined below. ‘The drug is preferably
completely released from the outer compartment from 45 to
50 minutes after irmnersion of the capsule into an aqueous
medium, the
release of the drug from the intermediate
compartment, for example, occurs from 10 min. to 1.5 hours
after immersion of the capsule in a liquid medium and the
release of the drug from the intermediate compartment is
completed from 4 to 5 hours after immersion of the capsule
in a liquid medium. The initial release of the drug from an
inner compartment of the drug delivery system occurs from
about 1 to 2 hours after immersion of the capsule in a liquid
medium and the release of the drug from an inner compart

create a limitation on the practice of the invention. The

50

coating procedures are known and acceptable for the prac
tice of the present invention and are outlined in Remington ’s

releasing compartment of the capsule. Alternately, the pep
tide drug may be introduced in only the pelletized inner
compartment of the multicompartment capsule.
To achieve colonic delivery of the capsule contents, the
capsules are coated with such polymer coatings as Eudragit
NE 30, Eudragit S100, cellulose acetate phthalate (CAP),

Mack Publishing Co., Easton, Pa., p. 1666-1675 and are

cellulose acetate succinate (CAS), cellulose acetate trimel
litate (CAT) or cellulose acetate butyrate (CAB). The above
polymers are acid resistant and dissipate from the surface of
the capsule via pH-dependent and time controlled release

incorporated herein by reference.

mechanisms known in the art.

Drugs to be administered in the drug delivery device
according to the present invention may be administered in

Examples of peptide drugs which may be used in the
capsule of the present invention include insulin, calcitonin,
interferon, interleukins and proteins in oral vaccines.
Examples of absorption enhancers are fatty acids, bile salts
such as sodium taurocholate, caprylate myristate, glycerides,
such as phosphatidyl choline, lecitins, salicylates and lauryl

Pharmaceutical Sciences, 18th Ed. (1990) published by

accordance with daily dosages known in the art and as
outlined in Remington ’s Pharmaceutical Sciences, 18th Ed.

(1990) published by Mack Publishing Co., Easton, Pa.
Examples of drugs to be delivered vaginally include but

sulfate. Examples of protease inhibitors for use in this

are not limited to spermicides such as Nonoxynol-9

(nonylphenoxypolyethoxy-ethanol), Octoxynol (diisobutyl
phenoxypolyethanol), p-methanylphenyl polyoxyethylene,
dodecamethylene glycol molureate, and sodium lauryl sul

65

embodiment of the invention, include but are not limited to

bestatin, leupeptin, chymostatin, pepstatin A, papain and

aprotinin.
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10
gelatin capsule with an outer layer of an active component
and an excipient was placed into 10 mL of water at pH 5.0

In a further advantageous embodiment of the invention,

the multicompartrnent capsule can be used in the design of
oral drug delivery dosage forms generally referred to as “one

and stirred at 24° C.
As can be seen from FIG. 2, the release of the active
ingredients, as measured by the rate of release of iodine,

a day” formulations. These formulations are particularly

useful in drug delivery to the elderly.
Compliance in dosage regimen is often di?icult to
achieve, particularly among the elderly. It is therefore

from the outer compartment of the capsule begins at

desirable, in the case of several drugs, to take one pill or

medium. Complete release of the PVP-I/N-9 from the outer

approximately one minute after immersion into an aqueous

dosage form per day (“one a day”). To achieve this regimen
the dosage form has to be a delivery system that can
continuously deliver the drug in a controlled release manner.

compartment of the capsule is attained within 45-50 minutes
10

The delivery of the drug from the multicompartment
capsule of the invention, in a preferred embodiment, is
continuous when the drug is appropriately distributed in

each of the capsule compartments. The capsule of the

determined by spectrophotometrically measuring the release
15

invention is much easier to produce and thus more cost

eifective than the commercially available PROCARDIA
XLTM tablet. In addition, the multicompartment capsule
dissipates completely prior to its elimination from the body
of a patient while the PROCARDIA XLTM tablet is elimi

20

nated in the feces intact, as an insoluble shell. This insoluble

patients.
25

example, ?avorings, colorings, sweeteners, fragrances,

example illustrated by FIG. 4, a hard size-0 capsule was
packed with about 170 mg of PVP, 170 mg of Ac-Di-Sol and

?ve pellets, each pellet being compressed under 600 to 1000
pounds of pressure from the mixture of 70% PVP-I/N-9,
15% calcium phosphate or lactose, 15% magnesium stearate
and 0% Ac-Di-Sol. As can be seen from FIG. 4, the rate of

release of PVP-I/N-9 from the inner compartment is slower
35

diluents, ?llers, preservatives, antioxidants, stabilizers, and
In an alternative embodiment, the drug delivery system of
the invention can be fabricated into any convenient shape for
insertion into a body cavity or for administration via the
gastrointestinal tract to meet a wide variety of functional

EXAMPLE 1

injection molding, compression molding, hot dipping,
45

Reference will now be made in detail to the ?gures

The various coating solutions form the creation of the
outer compartment are made according to the following
general procedure: Stock solutions of 30%-50% w/v of

CARBOWAXTM 8,000, 4,600, 3,350, or 1,450, 0%-30%

including preferred embodiments and methods of the present

w/v hydroxypropyl methylcellulose (HPMC) and

invention.
FIG. 1 illustrates a hard capsule 10 which is formed from

24%-66.7% w/v are made in water or alcohol.
50
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compartment 11 contains a powder formulation 13 which is
introduced into the hard capsule 10 and provides an

The appropriate amount of CARBOWAXTM stock solu
tion is mixed with aliquots of HPMC and PVP-I/N-9 stock
solutions in order to obtain the coating solution composition
which ranges from 10% to 12.5% wlv of CARBOWAX, 0%
to 10% w/v of HPMC and 8% to 50% w/v of PV'P-Im-9.

Subsequently, the hard gelatin capsule, size 0, is repeat
edly coated by the coating solution depending upon the
amount of solution desired for the outer compartment and
dried until a su?icient outer compartment is formed. The
extent of coating of the outer layer on a O-size hard gelatin
capsule ranges from about 10 to 80 mg. The amount of the

intermediate-speed release portion of the capsule. The inner
compartment of the capsule contains active ingredients
which are in the form of small pellets 14 and which release
their drug component or active agent more slowly than that
of the outer or intermediate compartments.
FIG. 2 illustrates the pro?le of the rate of release of

PVP-IIN-9, which possesses spermicidal and anti-HIV prop
erties at pH 5.0, from the outer compartment determined
spectrophotometrically measuring the release of iodine into
the medium. In the embodiment illustrated by FIG. 2, a hard

than the rate of release from the intermediate compartment,
as illustrated in FIG. 3, and the rate of release from the outer
compartment, as illustrated by FIG. 2.
While not intending to limit the scope of the invention in
any manner, the following examples are given to illustrate

various potential embodiments of the present invention.

requirements. Shaping can be affected, for example, by

gelatin, starch or hydrophilic polymer, and which comprises
a three compartment delivery system for its pharmacologi
cally active components. The outer compartment 12 incor
porates a drug and excipients into a layer which coats the
outer part of the capsule. This outer compartment represents
the rapid release portion of the capsule. The intermediate

hour after immersion of the capsule into the aqueous
medium, and attains a complete release Within 4 to 5 hours.
FIG. 4 illustrates the pro?le of the release of the drug
PVP-I/N-9 from the inner compartment, measured spectro
medium, in this case water with a pH of about 5.0. In the

lubricants.

extrusion, melt casting and similar techniques.

FIG. 3 further illustrates that the release of the drug from
the intermediate compartment begins approximately one

photometrically by following the release of iodine into the

optional ingredients as a conventionally used in the art, may

be employed. These optional ingredients include, for

of iodine into the medium, into water at pH 5.0 stirred at 24°

C. In the embodiment illustrated by FIG. 3, the rate of
release of drug from the intermediate compartment of the
capsule is slower than the rate of release of drug from the
outer compartment as illustrated in FIG. 2.

tablet has the potential to provide complications to some
Odoriferous agents which may be administered in the
capsule according to the invention, include but are not
limited to aromatic substances, fragrances, and absorbents.
Examples of fragrances which may be included in the
capsule are linalol and geraniol and etherial oils such as
lemon oil and lavender oil. In a preferred embodiment, the
capsule contains 10% citronella oil in admixture with olive
oil, as a fragrance extender and enhancer.
In addition to the foregoing critical components, various

after immersion of the capsule into the aqueous medium.
FIG. 3 illustrates the pro?le of the rate of release of
PVP-I/N-9 from the middle or intermediate compartment,

drug in this outer compartment ranges from about 3 to 64
mg.

EXAMPLE 2
65

A coating solution containing the anti-HIV drug, 3-azido
3-deoxythymidine (AZT) as the active component is made

according to the general procedure described in Example 1;

5,672,359
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12

1 mL of 50% w/v stock solution of CARBOWAXTM 1,450
is mixed with 3 mL of 20% w/v stock solution of AZT,

mg-170 mg) and disintegrant AC-DI-SOL (100-180 mg). A

producing the solution of CARBOWAXTM 1,450 andAZT in
a l2.5%/26.7% w/v ratio. The hard gelatin or starch capsule,

size 0, is coated by the coating solution and then dried. The
extent of the coating of the outer compartment on a O-sized
starch capsule ranges from about 20 to 30 mg. The amount
of AZT in this outer layer ranges from about 12 to 18 mg.
EXAMPLE 3

10

A coating solution was made from a coprecipitate of

hard capsule which is packed with a mixture of PVP-I/N-9
and AC-DI-SOL, is placed into 10 mL of water pH 5.0 and
stirred at 24° C. to 37° C. Concentration of solute (active
component PVP-I/N-9) in the release medium was followed
by monitoring the absorbance of iodine at 353 nm. Absor
bance is converted to concentration using absorptivity of
iodine determined from the calibration measurement. FIG. 3
is an example of PVP-I/N-9 release from a hard capsule size
0, packed with 170 mg of PVP-I/N-9 and 170 mg of
Ac-Di-Sol.

nonoxynol-9, polyvinyl pyrrolidone and iodine (PVP-I/N
9), sperrnicidal with anti-HIV properties, and CARBO
WAXTM 1,450 in the ratio of 50%/12% w/v. The solution
successfully coated a O-size gelatin or starch capsule. The
extent of coating of the outer surface of a O-size gelatin or

EXAMPLE 7
15

Solute release from the slow release inner compartment,

starch capsule by the above described method ranged from

represented by a multiparticulate form of PVP-I/N-9 and
other excipients is conducted under the following condi
tions: A hard capsule size 0 is packed with ?ller polyvi

10 to 80 mg. This amount of coating includes the active
component, in this case PVP-I/N-9, and the excipient, such
as CARBOWAXTM. The amount of the drug in the outer

mg and 5 pellets (3 mm diameter, 30 mg each) are dispersed
into the powder content of the hard capsule. The pellets are

layer ranged from 3 to 64 mg. The optimal ratio of drug to
excipients in the coating solution may be adjusted according
to the properties of the drug and the required extent of
coating in the outer layer of the capsule.

nylpyrrolidone (PVP) 170 mg, disintegrant Ac-Di-Sol 170
compressed from the mixture of PVP-IlN-9 7%—70% ,

calcium phosphate or lactose 84—10%, magnesium stearate

6%—20%, Ac-Di-SolTM 3%—0, using pressure of 600-1000
25

EXAMPLE4

A hard capsule packed With ?ller, disintegrant and ?ve
pellets is placed into 10 mL of water pH 5.0 and stirred at
24° C. or 37° C. Concentration of solute (active component
PVP-I/N-9) in the release medium is followed by monitoring

A coating suspension containing the antifungal drug
miconazole nitrate, 1-[2,4-Dichloro-B-(2,4-dichlorobenzyl)
oxy]-phenethyl-imidazole mononitrate (MONISI‘AT) as the
active component is made according to the following pro
cedure: 1.01 g. of miconazole nitrate is suspended in 2 mL
of 50% w/v solution of PVP (polyvinylpyrollidone) in
MeOH producing the coating suspension of PVP and

pounds.

30

miconazole in a 1:1 ratio. The hard gelation or starch 35

absorbance of iodine at 353 nm. Absorbance is converted to
concentration as described in Example 3. FIG. 4 is an

example of PVP-I/N-9 release from the slow compartment
of a hard gelatin capsule comprised from 5 PVP-I/N-9
pellets, dispersed into a powder containing 1'70 mg of PVP
and 170 mg of Ac-Di-Sol.

capsule, size 0, is coated by the coating suspension and then

EXAMPLE 8

dried. The extent of the loading of the outer layer on a O-size
hard capsule ranges from 110 to 216 mg. The amount of
miconazole nitrate in this outer layer ranges from 50 to 100
mg.

An example of intermediate compartment delivery is set
forth below. AO-size hard gelatin capsule was ?lled with 125
mg of PVP-I/Nonoxynol-9 powder and 100 mg. of an

coating solvent does not create a limitation on the practice

internally crosslinked sodium carboxymethyl-cellulose
disintegrant, USP purity, AC-DI-SOL. In this embodiment,

of the invention. The coating procedure can be practiced

the time of ?rst release of the drug into water with a pH of

This example illustrates the solubility of the drug in the
with a highly soluble drug as well as a completely insoluble

drug component or active agent.

5.0 at 24° C. was 2 to 3 hours.

,

.

45

EXAMPLE 9
EXAMPLES

Solute (active component) release from the rapidly releas
ing compartment of the outer layer is conducted under
following conditions: the hard gelatin capsule with the outer
layer of the active component and excipient is placed into 10

50

mL (this volume is used in order to achieve similar release

An example of inner compartment delivery is set forth
below. A 0-size hard capsule is packed with 170 mg of a PVP
?ller and 170 mg of AC-DI-SOLTM and ?ve pellets each
containing 10%—84% calcium phosphate, 6%—20% magne
sium stearate, 0%—3% AC-DI-SOL, and 7%—70% of the
desired drug, the time of ?rst release of the drug into water

environment for the vaginal application) of Water pH 5.0 and

of pH 5.0 at 24° C. was within a range of 1 to 2 hours. A
stirred at 24° C. or 37° C. Concentration of solute (PVP-II 55 complete release of the drug may be attained within 7 to 8

N-9) in the dissolution (release) medium is followed by

hours.

'

monitoring absorbance of iodine at 353 nm. Absorbance is

converted to concentration using absorptivity of iodine

EXAMPLE 10

determined from the calibration measurement. FIG. 2 rep
resents an example of PVP-I/N-9 release measured by the
rate of iodine release from the outer layer of the capsule.

Same as example 9, except that the ?ve pellets are coated
with a coating solution to prolong the time prior of drug

delivery from the pellets. This coating solution adopted for
sustained release in the gastrointestinal tract may contain
mixtures of waxes with glycerol monostearate, stearic acid,

EXAMPLE6

palrnitic acid, shellac and zein-polymers, ethylcellulose

Solute release from an intermediary compartment, repre

sented by the powder formulation of the drug and excipients
inside the capsule, is conducted under the following condi
tions: A hard capsule size-0, is ?lled with PVP-I/N-9 (125

65

acrylic resins and other materials apparent to those of skill
in the art as outlined in Remington’s Pharmaceutical Sci
ences.
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EXAMPLE 11

After the ?rst layer is established, the second layer is
created by dipping (or spraying) the capsule in an aqueous
dispersion of Eudragit NE30 and Eudragit S 100 SOD in a 7:3

An example of a complete three compartment capsule is
set forth below. A 0-size hard capsule is packed with 170 mg

ratio. The capsule is coated with a 10% cellulose acetate

of a PVP ?ller and 170 mg of AC-DI-SOLTM and ?ve 3 mm

phthalate in acetone/methanol (1:1 ratio) solution.

pellets, each containing 10%-84% calcium phosphate,
6%—20% magnesium stearate, 0%—3% AC-DI-SOL, and
7%-70% of acyclovir. The intermediary compartment, rep
resented by the powder formulation of acyclovir and excipi
ents is introduced inside the hard capsule surrounding the
pellet formulation. The intermediate compartment consists

EXAMPLE 17

10

of acyclovir powder (125 mg-170 mg) and disintegrant
AC-DI-SOLTM (100-180 mg).

One a Day Capsule
A zero size hard capsule is packed with 10 mg of
nifedipine, 200 mg of lactose, 100 mg of starch and 3 pellets.
Each of the pellets of the inner compartment contains 10

rag-20 mg of nifedipine, 10-84% of calcium phosphate,
60-20% of magnesium stearate.
The pellets are coated with a coating solution containing

A coating solution containing acyclovir as the active

component is made according to the general procedure

glyceryl monostearate 11% w/w, glyceryl distearate 16%
w/w, white wax USP 3% w/w, carbon tetrachloride 65%
w/W, PVP 2%, starch 2,8% titanium oxide 0.1%, CARBO

described in Example 1; 1 mL of 50% w/v stock solution of

CARBOWAXTM 1,450 is mixed with 3 mL of 20% w/V
stock solution of acyclovir, producing the solution of CAR
BOWAXTM 1,450 and acyclovir in a 10%/15% w/v ratio.
The hard gelatin or starch capsule, size 0, is coated by the
coating solution and then dried. The coating solution sur
rounds the capsule wall and thus surrounds the intermediate
drug powder compartment. The extent of the coating of the’

WAX 1400 0.1%.
The outer compartment is represented by 10-20 mg of
nifedipine 6-13 mg of CARBOWAX and 12-26 mg of

EXANIPLE 12

The purpose of the above description and examples is to
illustrate some embodiments of the present invention with
out implying any limitation. It will be apparent to those of
skill in the art that various modi?cations and variations may
be made in the capsule and method of the present invention
without departing from the spirit or scope of the invention.

HPMC or HPC.

EXAMPLE 18
outer compartment on a O-sized starch capsule ranges from
Sarne as Example 17, except that instead of HPMC the
about 20 to 30 mg. The amount of acyclovir in this outer
25
outer compartment contains PVP.
layer ranges from about 12 to 18 mg.

Same as example 11, except that the instead of acyclovir
the capsule contains an odoriferous agent.
30
EXA1VIPLE13

.

Same as example 11, except that the instead of acyclovir
the capsule contains Octoxynol, a spermicidal agent. The

We claim:

drug delivery system hard capsule is for vaginal delivery.
35

EXAMPLE 14

a. at least one slow rate releasing compartment compris

ing pellets or granules and at least one drug;
b. at least one intermediate rate releasing compartment,

Same as example 11, except that the instead of acyclovir
the capsule contains penicillin, an antibiotic. The drug

said intermediate releasing compartment comprising
powder or granules containing at least one drug;

delivery system hard capsule is for gastrointestinal delivery.

c. a hard capsule which houses said intermediate rate

EXAMPLE 15

releasing and said slow rate releasing compartments;

Peptide Capsule

and
d. a fast rate releasing outer layer comprising at least one

A zero size hard capsule is packed with 180 mg. of
taurocholate, 180 mg of sodium myristate, and 0.5 mg of
leupeptine, and 10 IU of insulin. As the inner compartment

drug and excipients, which surrounds completely said
hard capsule.
2. A hard capsule according to claim 1 wherein said fast
rate releasing layer releases said drug within about one
minute after immersion of said hard capsule into an aqueous
medium and the release is completed in about 40 to 50
minutes.
3. Ahard capsule according to claim 1 wherein the release
of said drug from said intermediate rate releasing compart

of the capsule, ?'te capsule contains three pellets, each
containing 10-84% of calcium phosphate, 60-20% of mag
nesium stearate, and insulin 40 IU.

.

1. A hard capsule drug delivery system comprising:

‘

The outer compartment consists of two layers. The ?rst
layer contains 20 mg. of sodium tanrocholate, 20 mg. of
sodium myristate, 0.5 mg. of leupeptine and 3.5 mg of
CARBOWAX 1450. After the ?rst layer is established, the

ment occurs from about 10 minutes to about 1.5 hours after
irmnersion of said hard capsule into an aqueous medium and

second layer is created by dipping (or spraying) the capsule
in an aqueous dispersion of Eudragit S100 and Eudragit NE
30D in a 3:7 ratio.

55

EXANIPLE 16
Same as example 15, except that a 0 size hard capsule is
packed with 180 mg of sodium taurocholate, 180 mg of
sodium caprylate, 0.5 mg of aprotinin, calcitonin. As the

is completed in about 4 to 5 hours.
4. Ahard capsule according to claim 1 wherein the release
of said drug from said slow rate releasing compartment
occurs from about 1 to 2 hours after immersion of said hard

capsule into an aqueous medium and is completed in about
7 to 8 hom's.

inner compartment of the capsule, the capsule contains three

5. A hard capsule according to claim 1 wherein said hard

pellets, each containing 10—84% of calcium phosphate,

capsule delivery system comprises a controlled release for
mulation for a single dosage per day delivery.
6. A hard capsule delivery system according to claim 1
wherein said delivery system is administered orally.
7. A hard capsule delivery system according to claim 1
wherein said delivery system is administered vaginally.

60-20% of magnesium stearate, and calcitonin.
The outer compartment consists of two layers. The ?rst
layer contains 20 mg of sodium caprylate, 20 mg of sodium
taurocholate, 0.5 mg of aprotinin and 3.5 mg of CARBO
WAX 1450.
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8. A hard capsule according to claim 1 wherein said drug
in said outer fast rate releasing layer is a protease inhibitor
and said drug in said intermediate rate releasing and said
slow rate releasing compartments is a peptide drug.
9. A hard capsule according to claim 1 wherein said drug
in said outer fast rate releasing layer and said intermediate
rate releasing compartment is a protease inhibitor and said
drug in said slow rate releasing compartment is ‘a peptide

15. Ahard capsule according to claim 1 wherein said outer

fast rate releasing layer further comprises components
selected from the group consisting of excipients, binders,
plasticizers and mixtures thereof in concentration of

l0-l2.5% by weight of said outer fast releasing layer.
16. A hard capsule according to claim 15 wherein drug
concentration in said outer fast rate releasing layer ranges
from 8 to 50% by weight of said outer fast rate releasing

drug.

10. A hard capsule of claims 8 and 9 wherein said slow

rate releasing compartment further comprises an absorption
enhancer.
11. A hard capsule according to claim 1 wherein said drug
in said outer fast rate releasing layer and said intermediate
rate and slow rate releasing compartments is nonoxynol-9.
12. A hard capsule according to claim 1 wherein said drug
in said outer fast rate releasing layer and said intermediate
rate and slow rate releasing compartments is an anti-HIV

drug.
13. A hard capsule according to claim 1 wherein said drug
in said outer fast rate releasing layer and said intermediate
rate and slow rate releasing compartments is nifedipine.
14. A hard capsule according to claim 1 wherein said drug
in said outer fast rate releasing layer and said intennediate
rate and slow rate releasing compartments is an antimicro

bial drug.

10

layer.
17. A hard capsule according to claim 1 wherein said
intermediate rate releasing and said slow rate releasing

compartments further comprise components selected from
the group consisting of excipients, binders, plasticizers and
15

mixtures thereof in concentration of 30 to 5 0% by weight of
said intermediate rate releasing and said slow rate releasing

compartments.
18. A hard capsule according to claim 17 wherein said
drug concentration in said intermediate rate releasing and
said slow rate releasing compartments ranges from 50 to
70% by Weight of said intermediate rate releasing and said
slow rate releasing compartments.
*****

